A Phase 3 interventional study of IBI112 and placebo in Psoriasis, sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.. Recruiting at 1 site in China. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-12-22.
Sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Phase 3, Interventional, and Treatment
The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of adolescent participants with moderate to severe plaque-type psoriasis.
1,899 studies on the registry are indexed under Psoriasis; 233 are open to participants now.
This study's planned enrollment of 104 is above the median of 70 across 1,447 interventional studies indexed under Psoriasis.
Browse Psoriasis studies →Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. is the lead sponsor of 7 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Males or females aged 12 to 18 years; Diagnosed with plaque psoriasis and a history of psoriasis ≥6 months; suitable for phototherapy and/or systemic treatment for psoriasis.
Exclusion Criteria:
History of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis Has received any therapeutic agent directly targeted to IL-17within 6 months of the first administration of study agent Has received any therapeutic agent directly targeted toTNF-a within 3 months of the first administration of study agent Has received any conventional therapeutic agent within 1 months of the first administration of study agent Has received any topic therapeutic agent within 2 weeks of the first administration of study agent Hsa received IBI112
Participants receive placebo through week 16,placebo participants will cross over to receive IBI112 through week 44
Drug: placebo
Participants receive IBI112 through week 44
Drug: IBI112
IBI112 by subcutaneous injection
placebo by subcutaneous injection
Percentage of patients achieving Psoriasis Area and severity index(PASI) 75 at week 16
PASI 75 is defined as at least a 75% reduction in PASI relative to baseline
Time frame: week 16
Percentage of patients achieving an static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) at Week 16
sPGA of psoriasis is used to determine the participant's psoriasis lesions overall.
Time frame: week 16
Percentage of patients achieving PASI 50 at week 16
PASI 50 is defined as at least a 50% reduction in PASI relative to baseline
Time frame: week 16
Percentage of patients achieving PASI 90 at week 16
PASI 90 is defined as at least a 90% reduction in PASI relative to baseline
Time frame: week 16
Percentage of patients achieving PASI 100 at week 16
PASI 100 is defined as at least a 100% reduction in PASI relative to baseline
Time frame: week 16
Percentage of patients achieving an sPGA 0 at week 16
sPGA of psoriasis is used to determine the participant's psoriasis lesions overall.
Time frame: week 16
Percentage of patients achieving an Children Dermatology life quality index (CDLQI) Score of 0 /1at week 16
The CDLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life
Time frame: week 16
Percentage of patients achieving PASI 75 at week 56
PASI 75 is defined as at least a 75% reduction in PASI relative to baseline
Time frame: week 56
Percentage of patients achieving PASI 90 at week 56
PASI 90 is defined as at least a 90% reduction in PASI relative to baseline
Time frame: week 56
Percentage of patients achieving PASI 100 at week 56
PASI 100 is defined as at least a 100% reduction in PASI relative to baseline
Time frame: week 56
Percentage of patients achieving an sPGA 0/1 at Week 56
sPGA of psoriasis is used to determine the participant's psoriasis lesions overall.
Time frame: week 56
Percentage of patients achieving an sPGA 0 at Week 56
sPGA of psoriasis is used to determine the participant's psoriasis lesions overall.
Time frame: week 56
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.